In 1776, doctors treated infections by draining blood from patients, a practice that may have hastened George Washington’s death from a throat infection in 1799. Today, life expectancy has more than doubled from 35 to 79 years, and the same infection would be treated with antibiotics. The transformation of medicine over the past two and a half centuries has been nothing short of revolutionary, with breakthroughs that once seemed unimaginable now saving millions of lives.
One of the most dramatic advances has been in vaccine technology. While Edward Jenner performed the first documented vaccination using cowpox in 1796, today’s mRNA vaccines represent a quantum leap. Developed by Penn Medicine Nobel laureates, these vaccines use genetic code to instruct cells to produce proteins that train the immune system. The technology, which proved critical during the Covid pandemic, is now being tested for influenza, cancer, tuberculosis and malaria. mRNA vaccines can be developed more quickly and at lower cost than traditional vaccines, opening the door to faster responses to emerging threats.
Cancer treatment has also seen a paradigm shift with CAR T-cell therapy. Scientists have developed a dual-receptor approach that adds a second receptor type to immune cells, helping them distinguish between cancer and healthy tissue. This engineered cell therapy appears to destroy tumors while leaving healthy cells alone, reducing the harmful side effects of conventional treatments. For solid tumors, which have been harder to treat, this advance is particularly promising.
Printing Tissues and a New Class of Medications
In regenerative medicine, 3D bioprinting is fabricating skin and tissues using bioink containing living human cells and supportive scaffolds. This technology may ease organ donor shortages within the next 5 to 20 years by replacing or regenerating damaged tissues and organs. Meanwhile, GLP-1 receptor agonists originally developed for Type 2 diabetes have reshaped obesity treatment. More than 30 million U.S. adults are estimated to have used a GLP-1 drug in 2025. On April 1, 2026, the Food and Drug Administration approved Foundayo, the second new oral medication from Eli Lilly. Gallup reported that the U.S. adult obesity rate declined from 39.9 percent in 2022 to 37.0 percent in 2025, representing 7.6 million fewer obese adults. Researchers are now exploring these drugs for heart failure, chronic liver disease, sleep apnea and substance abuse.
Artificial intelligence is also making its mark. AI scribes are being adopted in clinics to automate documentation, freeing physicians to focus on patients. The Medical Futurist Dr. Bertalan Meskó calls this “the biggest milestone in medicine in the last few decades,” though he cautions that adoption must be paired with oversight. Challenges remain. Health care spending in the United States reached $5.3 trillion in 2024, and nearly half of adults report difficulty affording care. As Mary Fissell, a historian of medicine at Johns Hopkins, notes, the U.S. leads in medical technology but lags in access. Yet the trajectory is clear: from bloodletting to bioprinting, the next 250 years hold promise we can only begin to imagine.